Literature DB >> 10807312

Cytokine signaling--regulation of the immune response in normal and critically ill states.

A Oberholzer1, C Oberholzer, L L Moldawer.   

Abstract

Cytokines are produced during the activation of innate and acquired immunity, and are the principal means for intercellular communication of a microbial invasion. Cytokines serve to initiate the inflammatory response and to define the magnitude and the nature of the acquired immune response. The response of critically ill patients to their injury and/or invading pathogens is dependent, in large part, on the pattern of cytokines which are produced. The immunologic response of critically ill patients can vary from a strongly proinflammatory response, characterized by increased production of tumor necrosis factor-alpha, interleukin (IL)-1, interferon (IFN)-gamma, and IL-12 to one predominantly of anergy, characterized by increased production of T(H)2 cytokines, like IL-10 and to IL-4. Therapeutic efforts to modify the host immune response in critical illness will require a more thorough understanding of the cytokine milieu and the factors that determine their production.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807312     DOI: 10.1097/00003246-200004001-00002

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  50 in total

Review 1.  Jaks, STATs, Cytokines, and Sepsis.

Authors:  Melanie J Scott; Christopher J Godshall; William G Cheadle
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

2.  Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers.

Authors:  J W Fijen; J G Zijlstra; P De Boer; R Spanjersberg; J W Tervaert; T S Van Der Werf; J J Ligtenberg; J E Tulleken
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

Review 3.  Overtraining, excessive exercise, and altered immunity: is this a T helper-1 versus T helper-2 lymphocyte response?

Authors:  Lucille Lakier Smith
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

4.  The immunomodulatory effects of hypertonic saline resuscitation in patients sustaining traumatic hemorrhagic shock: a randomized, controlled, double-blinded trial.

Authors:  Sandro B Rizoli; Shawn G Rhind; Pang N Shek; Kenji Inaba; Dennis Filips; Homer Tien; Fred Brenneman; Ori Rotstein
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

5.  Hypertonic saline resuscitation maintains a more balanced profile of T-lymphocyte subpopulations in a rat model of hemorrhagic shock.

Authors:  Yuan-qiang Lu; Xiu-jun Cai; Lin-hui Gu; Han-zhou Mu; Wei-dong Huang
Journal:  J Zhejiang Univ Sci B       Date:  2007-01       Impact factor: 3.066

6.  Acute low-dose endotoxin treatment results in improved whole-body glucose homeostasis in mice.

Authors:  Joseph R Stevens; Ryan P McMillan; Justin T Resendes; Shannon K Lloyd; Mostafa M Ali; Madlyn I Frisard; Stefan Hargett; Susanna R Keller; Matthew W Hulver
Journal:  Metabolism       Date:  2016-12-16       Impact factor: 8.694

7.  Genomic responses in mouse models greatly mimic human inflammatory diseases.

Authors:  Keizo Takao; Tsuyoshi Miyakawa
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

Review 8.  Pulmonary endothelium in acute lung injury: from basic science to the critically ill.

Authors:  S E Orfanos; I Mavrommati; I Korovesi; C Roussos
Journal:  Intensive Care Med       Date:  2004-07-16       Impact factor: 17.440

9.  Selective Th2 Upregulation by Crocus sativus: A Neutraceutical Spice.

Authors:  Sarang Bani; Anjali Pandey; Vijai K Agnihotri; Vijaylata Pathania; Bikram Singh
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-13       Impact factor: 2.629

10.  Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis?

Authors:  Sara E Perry; Sobhy M Mostafa; Richard Wenstone; Alan Shenkin; Paul J McLaughlin
Journal:  Intensive Care Med       Date:  2003-05-28       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.